Jul 8 2002
Bayer and Rhodia ChiRex have signed a licence agreement with the Massachusetts Institute of Technology (MIT) to develop catalytic processes fore the preparation of aromatic amines and ethers.
They will use technologies developed and patented by Prof. Stephen Buchwald of MIT. The technology was originally developed during the mid-90’s and evolved in the following years. It is based on efficient and innovative catalysts containing transition metal complexes, such as palladium, nickel and platinum and novel phosphines and ligands. They enable the transformation of common aromatic compounds, by converting them into C-N and C-O bond containing arylamine and arylether derivatives.
The catalysts are practical allow reactions to take place under mild conditions. They are highly selective and produce good yields.
The agreement allows Bayer and Rhodia Chirex to use the technology to develop intermediates and active ingredients used in life science applications, such as pharmaceuticals.
For more information on catalysts, click here.